Development of cancer therapeutic technology by functional measurement and control of cell division.

通过细胞分裂的功能测量和控制来开发癌症治疗技术。

基本信息

批准号：
18590540
负责人：
TANAKA Tomoo
金额：
$ 2.53万
依托单位：
Tokai University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2006
资助国家：
日本
起止时间：
2006 至 2007
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590540/
关键词：
Bradeion cancer marker cancer diagnosis development of cure monitor technique structure analysis measurement of enzyme activi fluorescence correlation spectroscopy(FCS)development of anticancer drua 癌マーカ Septin 4 GTPase 大腸菌前立腺癌 /

项目摘要

We have developed a technology for early diagnosis and cure monitor of cancer with Bradeion, a cancer marker we found. We have also developed the technology of Bradeion assay for discovering anticancer agent. As a result, we succeeded in the development of a cancer diagnosis system and kit. In addition, we succeeded in the structure analysis and the characterization of Bradeion, and development of the technology measuring inhibiting effect by the establishment of the method measuring its enzyme activity. In the last year of the study period, we used a fluorescence correlation spectroscopy (FCS) detecting single target molecule in patient serum. This full automatic machine with confocal laser microscope can measure using 10 pI of serum with a minute, and it costs only \1 per specimen. 3, 000 samples can be measured within one week. The data is reproducible in the samples stored at room temperature for a week. The samples preserved in a refrigerator are stable for a month.The structure presentation of a material with originality did not succeed after all until now, though many projects for protein structure analysis flooded. On the other hand, we succeed in the structure analysis of the cancer marker, Bradeion, as a result that we narrowed down to only one useful material and centralized the methodology that complies with a purpose. It is not only medicinal benefits but also less toxicity that is important to select the candidate of and cancer drug. We therefore equipped animal models for the toxic examination using a Drosophila and a chimera mouse(patented). We investigate an inhibitor from structure analysis of Bradeion protein and perform a high throughput screening using the FCS. We aim at development of an anticancer agent, by performing the evaluation of the candidate selected by the screening and a toxic examination by the animal model.

我们已经开发了一项技术，可以用Bradeion（我们发现的癌症标志物）进行早期诊断和治愈癌症的治疗。我们还开发了用于发现抗癌剂的大体型测定技术。结果，我们成功地开发了癌症诊断系统和试剂盒。此外，我们通过建立测量其酶活性的方法来成功进行结构分析和体征的表征以及测量抑制效果的技术的发展。在研究期的最后一年，我们使用了检测患者血清中单靶分子的荧光相关光谱（FCS）。这款具有共聚焦激光显微镜的完整自动机器可以使用10分钟的10 pi血清测量，并且每个样品的成本仅为\ 1。 3，000个样品可以在一周内测量。数据在室温下存储一周的样品中可再现。保存在冰箱中的样品稳定了一个月。尽管许多用于蛋白质结构分析的项目淹没了，但直到现在，具有独创性的材料的结构呈现才成功。另一方面，我们在癌症标志物Bradeion的结构分析中取得了成功，因此我们仅缩小到一种有用的材料，并集中了符合目的的方法。不仅是药用益处，而且毒性较小，这对于选择癌症和癌症药物很重要。因此，我们配备了使用果蝇和嵌合小鼠（获得专利）进行有毒检查的动物模型。我们从体脂蛋白的结构分析中研究了抑制剂，并使用FC进行了高吞吐量筛查。我们旨在通过对筛查选择的候选者进行评估和动物模型的有毒检查来开发抗癌剂。